PL3534904T3 - Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego - Google Patents
Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianegoInfo
- Publication number
- PL3534904T3 PL3534904T3 PL17803774.3T PL17803774T PL3534904T3 PL 3534904 T3 PL3534904 T3 PL 3534904T3 PL 17803774 T PL17803774 T PL 17803774T PL 3534904 T3 PL3534904 T3 PL 3534904T3
- Authority
- PL
- Poland
- Prior art keywords
- phthalazinedione
- dihydro
- amino
- treatment
- multiple sclerosis
- Prior art date
Links
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 title 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16002355 | 2016-11-07 | ||
| PCT/EP2017/001284 WO2018082814A1 (en) | 2016-11-07 | 2017-11-06 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3534904T3 true PL3534904T3 (pl) | 2022-07-18 |
Family
ID=57249636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17803774.3T PL3534904T3 (pl) | 2016-11-07 | 2017-11-06 | Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11007192B2 (pl) |
| EP (1) | EP3534904B1 (pl) |
| CA (1) | CA3042956A1 (pl) |
| DK (1) | DK3534904T3 (pl) |
| ES (1) | ES2918548T3 (pl) |
| PL (1) | PL3534904T3 (pl) |
| WO (1) | WO2018082814A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117586A1 (en) * | 2015-12-31 | 2017-07-06 | Bach Pharma, Inc. | Compositions and nethods for treating brain dysfunction |
| WO2020117151A2 (en) | 2018-06-21 | 2020-06-11 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A combination comprising fingolimod and modafinil |
| WO2019245512A2 (en) | 2018-06-21 | 2019-12-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A combination comprising fingolimod and at least one anti-epileptic agent |
| TR201818859A2 (tr) * | 2018-12-07 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon |
| TR201819202A2 (tr) * | 2018-12-12 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon |
| TR201819197A2 (tr) * | 2018-12-12 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bi̇r multi̇pl skleroz ajani ve en az bi̇r anti̇-epi̇lepti̇k ajan i̇çeren bi̇r kombi̇nasyon |
| TR201820976A2 (tr) * | 2018-12-28 | 2020-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar |
| US20200215149A1 (en) * | 2019-01-08 | 2020-07-09 | Christopher David Thompson | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same |
| EP3858358A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
| EP3858328A1 (en) * | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| AU2021244864B2 (en) | 2020-03-25 | 2025-12-18 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury |
| AU2021288757B2 (en) | 2020-06-10 | 2026-01-08 | Metriopharm Ag | Compound for the treatment of coronaviral infections |
| EP3981405A1 (en) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
| JP7824925B2 (ja) * | 2020-07-09 | 2026-03-05 | メトリオファーム アーゲー | グルココルチコイド節約剤 |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| JP2024516340A (ja) | 2020-12-02 | 2024-04-15 | メトリオファーム アーゲー | Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール |
| EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
| EP4209219A1 (en) * | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| EP4248963A1 (en) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester |
| EP4483879A1 (en) | 2023-06-29 | 2025-01-01 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders |
| WO2025067689A1 (en) | 2023-09-26 | 2025-04-03 | Metriopharm Ag | 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953799B1 (en) | 2002-10-30 | 2005-10-11 | Bach Pharma, Inc. | Modulation of cell fates and activities by diketo phthalazines |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| PL231885B1 (pl) | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| US8772294B2 (en) | 2010-03-01 | 2014-07-08 | Metriopharm Ag | Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
| WO2012127441A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| CN107567437B (zh) | 2014-12-18 | 2020-11-17 | 麦翠奥制药公司 | 5-氨基-2,3-二氢酞嗪-1,4-二酮钠盐的晶形、含其的药物制剂及其生产方法 |
-
2017
- 2017-11-06 ES ES17803774T patent/ES2918548T3/es active Active
- 2017-11-06 US US16/347,171 patent/US11007192B2/en active Active
- 2017-11-06 DK DK17803774.3T patent/DK3534904T3/da active
- 2017-11-06 PL PL17803774.3T patent/PL3534904T3/pl unknown
- 2017-11-06 CA CA3042956A patent/CA3042956A1/en active Pending
- 2017-11-06 EP EP17803774.3A patent/EP3534904B1/en active Active
- 2017-11-06 WO PCT/EP2017/001284 patent/WO2018082814A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3534904A1 (en) | 2019-09-11 |
| US20190358227A1 (en) | 2019-11-28 |
| EP3534904B1 (en) | 2022-03-16 |
| DK3534904T3 (da) | 2022-04-11 |
| US11007192B2 (en) | 2021-05-18 |
| WO2018082814A1 (en) | 2018-05-11 |
| CA3042956A1 (en) | 2018-05-11 |
| ES2918548T3 (es) | 2022-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3534904T3 (pl) | Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego | |
| IL276217A (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL274769A (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB2568809B (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB2568471B (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB201819573D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| GB201614522D0 (en) | Use of cannabinoids in the treatment of multiple myeloma | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| WO2016066744A3 (en) | Gip agonist compounds and methods | |
| GB2588261B (en) | Apparatus, use of the apparatus and arrangement | |
| SMT202500469T1 (it) | Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla | |
| SG11201607081RA (en) | Massage chair and method of driving the same | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| EP3302530A4 (en) | Cdh26 based therapeutic agents and their use | |
| IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| IL251840A0 (en) | Use of femiroplast in the treatment of severe asthma | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| PL3322480T3 (pl) | Bakterie Lactobacillus w leczeniu zaburzeń czynności serca | |
| IL269681A (en) | New methods for treating multiple sclerosis | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| EP3302456A4 (en) | Use of n-acetylcysteine amide in the treatment of acetaminophen overdose | |
| HK40037135A (en) | Use of hm4di in the treatment of seizure disorders |